Evidence map›Paper›PMID 41400360›Full record

ArticleAntimicrobial agents and chemotherapy2026

An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model of

Ciana L López, Guilhem Rerolle, Sarah Snyder, Osvaldo Arias, Abdullah Bashmail, Giovany Gonzalez, Debashish Roy, Brian Lee, Jessica M Snyder, Isabella Doorn and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ciana L LópezDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-3638-6454
Guilhem RerolleDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
Sarah SnyderDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.
Osvaldo AriasDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.
Abdullah BashmailDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
Giovany GonzalezDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
Debashish RoyDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.
Brian LeeDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
Jessica M SnyderDepartment of Comparative Medicine, University of Washington, Seattle, Washington, USA.
Isabella DoornDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
Sarah M BakerDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-0177-8135
Shelton W WrightDivision of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
T Eoin WestDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-5503-7204
Shawn J SkerrettDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9622-4070
Patrick S StaytonDepartment of Bioengineering, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-6939-6371

Funding

HOST DEFENSE TRAINING IN ALLERGY AND INFECTIOUS DISEASEST32AI007044 · NIAID · UNIVERSITY OF WASHINGTON · PI DAVID Neal FREDRICKS · 1985 to 2026
$14.6M
Engineered Antimicrobial Platform to Target Pulmonary Intracellular InfectionsR01AI134729 · NIAID · UNIVERSITY OF WASHINGTON · PI Shawn J. Skerrett, Patrick S. Stayton · 2018 to 2026
$4.9M
National Institute of Allergy and Infectious Diseases R01AI134729National Science Foundation Graduate Research Fellowship Program DGE-1762114NIAID NIH HHS R01 AI134729NIAID NIH HHS T32 AI007044
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsCiprofloxacinKlebsiella InfectionsKlebsiella pneumoniaeMacrophages, AlveolarPneumonia, BacterialProdrugsAnimalsDisease Models, AnimalFemaleLungMiceMice, Inbred C57BLPolymersAnti-Bacterial AgentsCiprofloxacinPolymersProdrugsalveolar macrophagesKlebsiella pneumoniaenanomaterialspneumoniapolymeric prodrugs

Identifiers

PMID41400360
PMCPMC12888862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.